Showing results (131-140 of 165) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteinsCatherine M Bollard, Stephen Gottschalk, Vicky Torrano, et al.Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.Journal of Geriatric Oncology|November 30, 2024
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)Myrna Candelaria, Luis Villela, Luis F Oñate-Ocana, et al.Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.Oncology Reports|July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.Hematological Oncology|June 24, 2017
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective RegistryIrene Biasoli, Nelson Castro, Marcia Delamain, et al.Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.Pageof 17